Resource implications of bortezomib therapy in a large UK cohort: An evaluation study. (December 2019)

• Record Type: Journal Article
• Authors: Djebbari, Faouzi; Tatarczuch, Maciej; Panitsas, Fotios; Vallance, Grant; Sultanova, Manuela; Kothari, Jaimal; Ramasamy, Karthik; Peniket, Andy
• Is Part Of: Journal of oncology pharmacy practice. Volume 25:Number 8(2019)
• Page Start: 1995
• Page End: 1998
• Publication Date: 2019-12
• Subjects: Bortezomib -- myeloma -- resource -- cost -- drug administration; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155219866500
• Languages: English
• ISSNs: 1078-1552

Abstract

Background: Bortezomib is a cornerstone in the management of multiple myeloma. It remains an attractive treatment option because it is efficacious, reasonably well tolerated and easy to administer. However, data on resource implications in the UK for both patients and healthcare providers are limited. Methods: We conducted a retrospective study of 127 patients to assess implications of bortezomib therapy on patients and healthcare resources. A patient-episode was defined as a patient attending the chemotherapy day treatment unit solely for bortezomib administration. Data were collected for the duration of therapy as follows: cost of drug calculated using the UK's bortezomib indicative price as per British National Formulary, cost of drug administration in the chemotherapy day treatment unit calculated using the National Health Service's schedule of service cost, time from check-in to drug administration, patient travel time and distance calculated using Google maps, and cost of travel. Results: Median drug cost and administration cost per patient were £8336 (£2084–£108, 368) and £4640 (£290–£15, 080), respectively. Median time from check-in to administration was 63 min (range 5–433), median travel time was 90 min (range 8–270) and 80 min (range 8–280) during peak and off-peak periods, respectively. Median return travel distance was 33.4 miles (range 1.2–224) for travel cost per patient per trip was £8.35–£13.20. Conclusions: Our real-world resource analysis demonstrated that delivering bortezomib therapy can be associated with significant cost and time implications for patients and healthcare providers. Our study method sets a basis for evaluating resource implications of other novel approaches to myeloma therapy.